PSMA changes in the peripheral nociceptive system in 5 pain phenotypes

PSMA changes in the peripheral nociceptive system in 5 pain phenotypes - Pain-Vis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014335

Enrollment

100

Registered

2018-04-16

Start date

2018-04-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R52.9

Interventions

Group 1: Diabetes mellitus-induced neuropathic pain Prescreening is performed as part of clinical routine by the Clinic for Anaesthesiology and Surgical Intensive Care. All the patients recruited to h

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Diabetes mellitus-induced neuropathic pain 1. capable of giving consent 2. age = 50 years 3. diabetes mellitus 4. neuropathic pain Cancer chemotherapy-induced neuropathy pain 1. capable of giving consent 2. age = 50 years 3. neuropathic pain 4. group after chemotherapy Nerve injury-induced neuropathic pain 1. capable of giving consent 2. age = 50 years 3. neuropathic pain after nerve injury Reactive/inflammation-induced visceral pain 1. capable of giving consent 2. age = 50 years 3. visceral pain of reactive or inflammatory origin inflammatory arthrosis 1. capable of giving consent 2. age = years 3. inflammatory arthrosis 4. pain as a result of inflammatory arthrosis

Exclusion criteria

Exclusion criteria: Diabetes mellitus-induced neuropathic pain 1. any radiation exposure for scientific purposes within the last 10 years. Cancer chemotherapy-induced neuropathy pain 1. any radiation exposure for scientific purposes within the last 10 years. Nerve injury-induced neuropathic pain 1. any radiation exposure for scientific purposes within the last 10 years. Reactive/inflammation-induced visceral pain 1. any radiation exposure for scientific purposes within the last 10 years. inflammatory arthrosis 1. any radiation exposure for scientific purposes within the last 10 years.

Design outcomes

Primary

Measure	Time frame
Signal intensity and segmental extension of the PSMA tracer over a period of 1-3 hours after tracer injection in relation to reference regions such as musculature	—

Secondary

Measure	Time frame
- Signal intensity of the PSMA tracer in reference regions (e.g. salivary glands, blood pool, liver, spleen and muscles) - Time course of PSMA PET signal intensity in reference regions (e.g. salivary glands, blood pool, liver, spleen and muscles) - Comparison of PSMA PET signal intensity in different pain conditions	—

Countries

Germany

Contacts

Public ContactSimone Stockter

Klinik und Poliklinik für Nuklearmedizin

Simone.Stockter@uk-koeln.de0221-478-7534

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026